DR info

Clinical trials : 4 / Drugs : 9 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 4

Drugs and their primary sponsors and trial info

PLA-PRU-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PLA-PRU-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PRU-PLA-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PRU-PLA-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
Rifaximin
   Ohkubo Hidenori
      2019   Phase 2   JPRN-jRCT2031190137   Japan;
Rifaximin oral tablet
   Yokohama City University
      2019   Phase 2   NCT04118699   Japan;
TD-5108 hydrochloride
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;
THRX-199687 hydrochloride
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;
Velusetrag
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;